Rijnstate Ziekenhuis Stichting

The site runs a broad portfolio of oncology studies focused on neoplasms such as lung cancer, breast cancer, bladder cancer, and gastric cancer. These trials mainly aim to test new treatment options, compare them with current care, and improve outcomes for people with advanced or hard-to-treat cancers.

• Studies in non-small cell lung cancer, small cell lung cancer, and other thoracic cancers are evaluating whether newer immunotherapy and targeted approaches can improve survival and disease control.
• Research in urothelial carcinoma and bladder cancer is examining more effective perioperative and first-line treatment strategies for patients with localized or advanced disease.
• Trials in breast cancer, including triple negative breast cancer and hormone receptor–positive disease, are testing ways to delay recurrence and strengthen long-term control.
• Hematology studies cover acute myeloid leukemia, chronic lymphocytic leukemia, lymphoma, and multiple myeloma, with a focus on improving response rates and treatment durability.

Overall, the oncology program at Rijnstate Ziekenhuis Stichting combines treatment innovation with practical clinical questions, helping refine care for patients with both common and rare cancers.

A major part of the trial activity addresses cardiovascular diseases and metabolic disorders, including atherosclerotic cardiovascular disease, atrial fibrillation, heart failure, myocardial infarction, stroke, obesity, and type 2 diabetes. The studies are designed to improve prevention, reduce complications, and test better ways to protect patients at high risk.

• Several trials focus on lowering the risk of major adverse cardiovascular events through newer lipid-lowering and anti-inflammatory approaches.
• Research in atrial fibrillation and stroke prevention is comparing treatments that may better balance clot prevention and bleeding risk.
• Studies in heart failure and kidney-related complications are evaluating therapies intended to reduce hospitalizations and cardiovascular death.
• Metabolic research includes obesity, hypertriglyceridemia, and related risk factors, with the goal of improving long-term cardiometabolic health.

This work reflects a strong interest in preventing first and recurrent events while improving everyday care for patients with complex cardiovascular risk.

The site also contributes to research in respiratory tract diseases, infectious diseases, and critical care. Current studies include COPD, asthma, pneumonia, influenza, and serious bacterial infections, with the aim of improving symptom control, recovery, and survival.

• Trials in severe asthma and chronic cough are exploring better ways to manage persistent airway inflammation and breathing problems.
• Research in pneumonia, influenza, and Staphylococcus aureus bacteremia is focused on reducing complications and improving outcomes in hospitalized patients.
• Critical care studies address respiratory distress, ventilation-related challenges, and acute illness management to support safer treatment decisions.
• Additional work looks at whether supportive therapies can reduce inflammation and improve recovery in severe acute conditions.

These studies show a practical focus on common, high-burden conditions where better treatment choices can make a meaningful difference.

The Medical Oncology department has a strong program in hematic and lymphatic diseases, especially acute myeloid leukemia, chronic lymphocytic leukemia, lymphoma, myelodysplastic syndrome, and multiple myeloma. The trials aim to improve disease control, deepen responses, and support more durable treatment benefit.

• Leukemia studies are testing new combinations for newly diagnosed and relapsed disease, with attention to patients who may not tolerate intensive treatment.
• Lymphoma research includes Hodgkin lymphoma, follicular lymphoma, diffuse large B-cell lymphoma, and marginal zone lymphoma, often comparing newer targeted options with established therapy.
• Myeloma trials are examining ways to monitor disease more precisely and improve outcomes in both newly diagnosed and relapsed settings.
• Several studies also explore treatment strategies that may preserve quality of life while maintaining anti-cancer effectiveness.

This area highlights the site’s expertise in blood cancers and its interest in refining treatment for patients with complex, long-term hematologic disease.

Another active theme is digestive system disease research, covering esophageal cancer, gastric cancer, rectal cancer, colorectal cancer, Crohn's disease, ulcerative colitis, and acute pancreatitis. These trials focus on improving cancer control, easing symptoms, and finding better supportive treatments for inflammatory and acute gastrointestinal conditions.

• Studies in gastroesophageal cancer and rectal cancer are evaluating new approaches to strengthen treatment effectiveness before or after surgery.
• Research in inflammatory bowel disease is looking for better symptom management and longer-lasting disease control.
• Trials in acute pancreatitis are testing whether supportive therapies can reduce organ failure and improve recovery.
• Additional work includes gastroparesis and other digestive disorders where better symptom relief and quality of life are important goals.

Together, these studies reflect a mix of cancer-focused and non-cancer gastrointestinal research aimed at improving both survival and day-to-day functioning.

The site also participates in trials across nervous system diseases and mental disorders, including stroke, multiple sclerosis, intracerebral haemorrhage, insomnia, and depression. The main purpose is to improve recovery, reduce disability, and support better symptom management.

• Stroke research is testing ways to improve neurological recovery and prevent later complications after acute events.
• Studies in multiple sclerosis are comparing treatment options for relapsing and progressive disease.
• Work in intracerebral haemorrhage is exploring whether targeted therapies can limit secondary brain injury.
• Additional research addresses sleep, mood, and quality-of-life concerns that can strongly affect daily functioning.

This portfolio shows attention to both acute neurological care and longer-term rehabilitation needs, with an emphasis on meaningful patient-centered outcomes.